AIM movers: Faron Pharmaceuticals FDA progress and Titon disappoints

Faron Pharmaceuticals (LON: FARN) has met with the FDA in the US to discuss the plan for registration for bexmarilimab for treating myelodysplastic syndrome (MDS). The FDA acknowledged the difficulty of running a randomised study in the relapsed/ refractory setting and proposed a phase III study in frontline high risk MDS. This study targets a larger number of patients and could speed up approval for the cancer treatment. The share price increased 31.3% to 130p.

Oracle Power (LON: ORCP) says drilling results from the Northern Zone project in Western Australia has intersected gold mineralisation to the north and south of the maiden resource. There is shallower supergene gold mineralisation than anticipated. Further drilling is planned to the north east. The share price rose 11.9% to 0.0235p.

- Advertisement -

Kidney diagnostics company Renalytix (LON: RENX) is collaborating with the Steno Diabetes Center in Copenhagen. This is a move to expand outside of the US. The initial focus is implementing the KidneyIntelX diagnostic in Copenhagen. This could help to open up the European market. The share price improved 9.09% to 12p.

Healthcare services provider Totally (LON: TLY) has secured extensions to three elective care contracts worth a total of £8m. These contracts help the NHS to reduce waiting lists. There are three extensions to urgent care services contracts worth £3.5m in total. This helped the share price rebound 8.97% to 7.9p.

FALLERS

Trading has been tougher than expected at window components supplier Titon (LON: TON), which has led to forecast downgrades. An increased loss of £1.5m is expected this year. Chief executive Tom Carpenter was appointed two months ago and restructuring measures will reduce costs. There are signs of demand recovering, but orders are slower in turning into sales.  The share price slipped 12.5% to 70p.

- Advertisement -

Tavistock Investments (LON: TAVI) is launching a claim against investment manager Titan following its decision to terminate the relationship. Tavistock Investments denies Titan’s accusation of wrongful conduct. Titan’s portfolios have been in the 99th and 100th percentiles and performed well below benchmark. The share price fell 6.45% to 2.9p.

Four directors of SIMEC Atlantis Energy (LON: SAE) have been buying shares. Chief executive Graham Reid bought 225,780 shares at 2.158p each, finance director Simon Hirst 850,000 shares at 1.9875p each, chairman Duncan Black 271,951 shares at 2p each and non-exec John Woodley 500,000 shares at 2.0025p each. Even so, the share price is 4.44% lower at 2.15p.

Ex-dividends

Anpario (LON: ANP) is paying a final dividend of 7.5p/share and the share price fell 5p to 332.5p.

Cake Box (LON: CBOX) is paying a final dividend of 6.1p/share and the share price is 7.5p lower at 177.5p.

Character Group (LON: CCT) is paying an interim dividend of 8p/share and the share price slipped 6p to 296p.

Caledonia Mining Corp (LON: CMCL) is paying a dividend of 14 cents/share and the share price is unchanged at 795p.

Heavitree Brewery (LON: HVT) is paying an interim dividend of 2.25p/share and the share price is unchanged at 265p.

i3 Energy (LON: I3E) is paying a dividend of 0.26p/share and the share price is down 0.285p to 9.895p.

Kitwave (LON: KITW) is paying an interim dividend of 3.85p/share and the share price is 37.5p higher at 346.25p.

Marks Electrical (LON: MRK) is paying a final dividend of 0.66p/share and the share price is unchanged at 70p.

MS International (LON: MSI) is paying a final dividend of 16.5p/share and the share price slipped 17,5p to 1087.5p.

Real Estate Investors (LON: RLE) is paying a dividend of 0.5p/share and the share price dipped 0.5p to 36p.

Sanderson Design Group (LON: SDG) is paying a final dividend of 2.75p/share and the share price fell 2p to 90.5p.

Shoe Zone (LON: SHOE) is paying an interim dividend of 2.5p/share and the share price declined 2.5p to 145p.

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This